PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 11218791

[Eptifibatide (Integrilin)].

L Holmvang·P Grande
View original source ↗Export metadata ↓

Abstract

Eptifibatide (Integrilin) is a specific blocker of the glycoprotein IIb/IIIa receptor and an effective inhibitor of platelet aggregation. It reduces coronary events in patients with acute coronary syndromes and no elevation in the electrocardiographic ST segment. The present summary discusses the indications for the use of eptifibatide/Integrilin based on recent clinical trials and cost-benefit analyses.

Explore related subjects

EptifibatideHumansInfusions, ParenteralInjections, IntravenousPeptidesPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

L Holmvang, P Grande. 2001-01-22. [Eptifibatide (Integrilin)].. https://pubmed.ncbi.nlm.nih.gov/11218791/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2000

Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment.

Randomized clinical trials of glycoprotein IIb/IIIa integrin inhibition during percutaneous coronary intervention and as adjunctive treatment of acute coronary syndromes have shown impressive clinical efficacy in reducing the morbidity and mortality rates of cardiovascular disease. Three agents are currently available in the United States: abciximab (ReoPro), eptifibatide (Integrilin), and tirofiban (Aggrastat). Pharmacodynamic studies show that abciximab is a high-affinity agent with a low dissociation constant; eptifibatide and tirofiban are high-specificity agents with higher dissociation constants and concentration-dependent antiplatelet effects. This article first reviews the relevant pharmacokinetic and pharmacodynamic properties of each of the agents. These principles are then applied to a discussion of the 4 primary clinical issues concerning their use: prevention of untoward bleeding, algorithms for acute reversal, recognition and treatment of thrombocytopenia, and the issue of readministration.

Eptifibatide↗